Skip to main content
. Author manuscript; available in PMC: 2020 Feb 18.
Published in final edited form as: Drug Alcohol Depend. 2017 May 26;177:84–92. doi: 10.1016/j.drugalcdep.2017.03.029

Table 5.

Associations of demographic, laboratory, and clinical factors with hepatic triglyceride by cocaine use status, robust regression analysis.

Variable Never use cocaine
 Chronic cocaine users
Univariate model
 Final multivariate model
 Univariate model
 Final multivariate model
regression estimate (SE) p-value regression estimate (SE) p-value regression estimate (SE) p-value regression estimate (SE) p-value
Age (year) 0.0030(0.0125) 0.81 0.0113(0.0265) 0.67
Male sex −0.3257(0.3219) 0.31 −0.3310(0.3343) 0.32
Years of cigarette smoking 0.0038(0.0182) 0.83 −0.0018(0.0133) 0.89
Number of cigarettes smoked/day
 ≤ 3 reference reference
 > 3 but < = 10 0.2723(0.3184) 0.39 0.1129(0.3817) 0.77
 > 10 −0.7142(0.6843) 0.30 0.4053(0.4854) 0.40
Years of alcohol use −0.0062(0.0181) 0.73 0.0113(0.0128) 0.37
Number of alcohol drinks/week
 ≤ 2 reference reference
 > 2 but < = 6 0.7437(0.3656) 0.04 0.6947(0.3981) 0.09
 > 6 0.0854(0.4422) 0.84 0.6415(0.3828) 0.09
Heavy drinking 0.0458(0.4991) 0.92 0.3920(0.3796) 0.30
Hypertension −0.3153(0.3650) 0.39 0.1919(0.4522) 0.67
Diabetes Not estimable 0.0439(0.8139) 0.95
hsCRP (mg/dL) 0.0161(0.0450) 0.72 −0.0645(0.0533) 0.23
Systolic BP (mmHg) −0.0006(0.0081) 0.94 0.0098(0.0098) 0.32
Diastolic BP (mm Hg) −0.0108(0.0115) 0.35 0.0217(0.0147) 0.15
Fasting glucose (mg/dL) −0.0011(0.0120) 0.93 0.0037(0.0063) 0.56
BMI (kg/m2) 0.0589(0.0261) 0.024 0.0590(0.0296) 0.046 0.1006(0.0302) 0.0008
Total cholesterol (mg/dL) 0.0060(0.0036) 0.10 0.0070(0.0036) 0.049 0.0072(0.0034) 0.036
HDL-C (mg/dL) 0.0041(0.0097) 0.67 −0.0034(0.0078) 0.66
Triglycerides (mg/dL) −0.0020(0.0027) 0.045 0.0068(0.0017) < 0.0001
2013 ACC/AHA risk (%) 1.8269(2.0718) 0.37 1.3974(1.7447) 0.42
HCV infection 1.0792(0.4460) 0.015 0.4194(0.3273) 0.20
Years since HIV diagnosed −0.0287(0.0220) 0.19 −0.0100(0.0232) 0.66
CD4 count nadir (cells/mm3) −0.0031(0.0024) 0.20 0.0010(0.0012) 0.40
CD4 count at MRS (cells/mm3) 0.0012(0.0009) 0.17 −0.0003(0.0007) 0.71
highest HIV RNA (copies/mL) 0.0364(0.0978) 0.71 0.0273(0.1268) 0.83
HIV RNA at MRS (copies/mL) −0.0690(0.0901) 0.44 −0.0558(0.0763) 0.46
Months of NRTI use 0.0013(0.0016) 0.43 0.0017(0.0032) 0.58
Months of NNRTI use −0.0003(0.0031) 0.91 −0.0066(0.0055) 0.22
Months of PI use 0.0019(0.0016) 0.23 0.0076(0.0033) 0.021 0.0070(0.0006) 0.033

Abbreviations: hsCRP, high-sensitivity C-reactive protein; BP, blood pressure; glucose, fasting glucose; BMI, body mass index (kg/m2); LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; 2013 ACC/AHA risk, cardiovascular risk score based on 2013 ACC/AHA CV risk calculator (Goff et al., 2014); HCV infection, persons who were positive for HCV antibodies by 2 enzyme immunoassay were considered to be HCV antibody positive and are hereafter referred to as HCV infected; CD4 count nadir, the lowest CD4 count since HIV diagnosis; CD4 count at MRS, the CD4 count when magnetic MR spectroscopy was performed; HIV RNA at MRS, the HIV viral load when magnetic MR spectroscopy was performed; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.